Who
David D. Meek
Director
Company insider
Files Form 4 as: Director, Cullinan Therapeutics; Director, uniQure; Director, Fusion Pharmaceuticals; Chief Executive Officer, Mirati Therapeutics; Director, Entasis Therapeutics Holdings; EVP and President, Oncology, Baxalta; Chief Commercial Officer, Endocyte.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $751K
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 3 Aug 2012
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,319 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,319 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $54K1,993 at $27.06 | filing |
| 11 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $54K1,993 at $27.06 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —7,550 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,980 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,980 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —7,550 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $31K2,112 at $14.45 | filing |
| 12 Jun 2025filed 16 Jun 2025 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,513 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,630 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —7,970 at $0.00 | filing |
| 19 Jun 2024filed 21 Jun 2024 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,840 at $0.00 | filing |
| 19 Jun 2024filed 21 Jun 2024 | QURE uniQureBiotechnology | SEC FORM 4 Code A | —8,080 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $11K2,229 at $5.12 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —34,000 | filing |
| 15 May 2024filed 16 May 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,618 at $0.00 | filing |
| 16 Oct 2023filed 16 Oct 2023 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 16 Jun 2023filed 20 Jun 2023 | QURE uniQureBiotechnology | SEC FORM 4 Sold | $43K2,290 at $18.85 | filing |
| 13 Jun 2023filed 20 Jun 2023 | QURE uniQureoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,060 at $0.00 | filing |
News
Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)QURE · tickerreport.com · 13 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastQURE · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name David D. Meek; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.